抗体-药物偶联物:加拿大批准ADCETRIS与AVD联合化疗用于初治型晚期霍奇金淋巴瘤

2019-05-05 不详 网络

Seattle基因公司近日宣布,加拿大卫生部已批准其补充新药申请,允许ADCETRIS(brentuximab vedotin)与AVD(阿霉素、长春碱和达卡巴嗪)联合化疗用于初治型晚期霍奇金淋巴瘤(HL)患者。

Seattle基因公司近日宣布,加拿大卫生部已批准其补充新药申请,允许ADCETRISbrentuximab vedotin)与AVD(阿霉素、长春碱和达卡巴嗪)联合化疗用于初治型晚期霍奇金淋巴瘤HL)患者。该批准是基于IIIECHELON-1临床试验的阳性结果,在该试验中,ADCETRIS分别联合AVDABVD(阿霉素、博来霉素、长春碱和达卡巴嗪)。ADCETRIS是针对CD30的抗体-药物偶联物(ADC),CD30是经典HL的细胞表面标志物,并在几种类型的外周T细胞淋巴瘤PTCL)的细胞膜上表达。

加拿大不列颠哥伦比亚大学的Kerry Savage博士说:加拿大卫生部批准ADCETRIS联合AVD治疗晚期(第四阶段)霍奇金淋巴瘤是几十年来取得的重大进展。晚期霍奇金淋巴瘤往往更具攻击性,难以治疗。与标准的ABVD相比,ADCETRIS联合AVD的方案表现出更高的疗效


原始出处:

http://www.firstwordpharma.com/node/1638591?tsid=4#axzz5mwpWeWX8

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]
    2019-05-07 zhaojie88
  6. [GetPortalCommentsPageByObjectIdResponse(id=1947276, encodeId=d931194e2762d, content=<a href='/topic/show?id=94841958f6' target=_blank style='color:#2F92EE;'>#Adcetris#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1958, encryptionId=94841958f6, topicName=Adcetris)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTIOca9icPByKxo3ZRUrvuibf7tWt7EScQ1NEiaKy4NCUctSU2jDjOayLicDIaicwUxaQhJ1SZKdEevgjRg/132, createdBy=4f272500131, createdName=若水123, createdTime=Sat Dec 28 02:52:00 CST 2019, time=2019-12-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2043061, encodeId=a5232043061ff, content=<a href='/topic/show?id=43a35989249' target=_blank style='color:#2F92EE;'>#晚期霍奇金淋巴瘤#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59892, encryptionId=43a35989249, topicName=晚期霍奇金淋巴瘤)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec25412, createdName=yangpeizhi, createdTime=Fri Sep 13 01:52:00 CST 2019, time=2019-09-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1646576, encodeId=4a3a16465e688, content=<a href='/topic/show?id=c27b55169f7' target=_blank style='color:#2F92EE;'>#抗体-药物偶联物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=55169, encryptionId=c27b55169f7, topicName=抗体-药物偶联物)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=854423309455, createdName=lvygwyt2789, createdTime=Fri Dec 13 17:52:00 CST 2019, time=2019-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312609, encodeId=5b8a131260939, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352936, encodeId=1a9b135293629, content=<a href='/topic/show?id=3ee33029dd' target=_blank style='color:#2F92EE;'>#AVD#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3029, encryptionId=3ee33029dd, topicName=AVD)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1411739, encodeId=3cc51411e3936, content=<a href='/topic/show?id=a53e806837f' target=_blank style='color:#2F92EE;'>#联合化疗#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=80683, encryptionId=a53e806837f, topicName=联合化疗)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ebf32807001, createdName=oliver170, createdTime=Tue May 07 01:52:00 CST 2019, time=2019-05-07, status=1, ipAttribution=)]

相关资讯

姜文奇教授:Brentuximab Vedotin联合AVD一线治疗中晚期霍奇金淋巴瘤可显著改善无复发生存

大约30%的III/IV期霍奇金淋巴瘤(HL)患者一线ABVD方案治疗后会出现疾病复发或耐药。Brentuximab Vedotin(SGN-35)为抗CD30单克隆抗体偶联抗微管蛋白药物,美国FDA已批准用于治疗ASCT失败后或不适合行ASCT且至少二次化疗失败后HL患者的治疗,是近30年唯一被批准用于治疗HL的新药。Brentuximab Vedotin作为复发难治HL移植后维持治疗的III期